FDA.reportPublic FDA data

tremelimumab-actl 25 MG in 1.25 ML Injection

RxCUI
2619325
RxNorm name
tremelimumab-actl 25 MG in 1.25 ML Injection
Display name
tremelimumab-actl 25 MG in 1.25 ML Injection
Full name
tremelimumab-actl 25 MG in 1.25 ML Injection
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:39:01

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761289Imjudotremelimumab-actl351(a)Rx2026-06-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
IMJUDOTREMELIMUMABAstraZeneca Pharmaceuticals LP6690679c-be2f-4588-a2e4-89fff74dd6be2024-07-24Warnings, Adverse reactionsExact identifier
rxcui: 2619325

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set IDRxNorm stringTTYSPL versionLabelEffective
6690679c-be2f-4588-a2e4-89fff74dd6betremelimumab-actl 25 MG in 1.25 ML InjectionPSN14These highlights do not include all the information needed to use IMJUDO safely and effectively. See full prescribing information for IMJUDO. IMJUDO ® (tremelimumab-actl) injection, for intravenous use Initial U.S. Approval: 202220240724
6690679c-be2f-4588-a2e4-89fff74dd6be1.25 ML tremelimumab-actl 20 MG/ML InjectionSCD14These highlights do not include all the information needed to use IMJUDO safely and effectively. See full prescribing information for IMJUDO. IMJUDO ® (tremelimumab-actl) injection, for intravenous use Initial U.S. Approval: 202220240724
6690679c-be2f-4588-a2e4-89fff74dd6betremelimumab-actl 25 MG per 1.25 ML InjectionSY14These highlights do not include all the information needed to use IMJUDO safely and effectively. See full prescribing information for IMJUDO. IMJUDO ® (tremelimumab-actl) injection, for intravenous use Initial U.S. Approval: 202220240724
6690679c-be2f-4588-a2e4-89fff74dd6betremelimumab-actl 20 MG/ML per 1.25 ML InjectionSY14These highlights do not include all the information needed to use IMJUDO safely and effectively. See full prescribing information for IMJUDO. IMJUDO ® (tremelimumab-actl) injection, for intravenous use Initial U.S. Approval: 202220240724